AccessPharmacy | Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e

Librarians Glossary Newsletter Subscriptions About Editor Contact Us Help Quick Test

Log In

select

disable autosuggest

advanced search

Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e

Laurence L. Brunton, editor-in-chief
John S. Lazo and Keith L. Parker, Associate Editors

Editors of the online edition:
Laurence L. Brunton, editor-in-chief
Associate Editors: Keith L. Parker, Nelda Murri, Donald K. Blumenthal, and Björn C. Knollmann

In Memoriam
We are sad to report the death of our colleague and friend, Keith Parker. He will always be remembered for his energy, breadth of knowledge, and sparkling ideas. Memorial contributions may be made to endocrinology research at the Keith L. Parker Fund, UT Southwestern Medical Center, P.O. Box 910888, Dallas, Texas 75391-0888.

Preface Preface to the Online Edition Copyright Contributors

CONTENTS

I. General Principles
Chapter 1.	Pharmacokinetics and Pharmacodynamics: The Dynamics of Drug Absorption, Distribution, Action, and Elimination
Chapter 2.	Membrane Transporters and Drug Response
Chapter 3.	Drug Metabolism Latest Update: 12/03/09: St. John’s Wort: A Mini-Review of its Pharmacokinetics and Anti-Depressant Effects
Chapter 4.	Pharmacogenetics Latest Update: 09/08/06: Hot Topic: Warfarin Pharmacogenomics
Chapter 5.	The Science of Drug Therapy Latest Update: 03/03/09: Clinical Pharmacist's Corner: A Look Back at 2008: A Synopsis of Noteworthy FDA Approvals
II. Drugs Acting at Synaptic and Neuroeffector Junctional Sites
Chapter 6.	Neurotransmission: The Autonomic and Somatic Motor Nervous Systems Multimedia: Cholinergic Neuroeffector Junction: Molecular physiology and pharmacology of the cholinergic neuroeffector junction, including the actions of hemicholinium, vesamicol, and botulinum toxin. Multimedia: Adrenergic Neuroeffector Junction: Molecular physiology and pharmacology of the adrenergic neuroeffector junction, including the actions of cocaine and reserpine.
Chapter 7.	Muscarinic Receptor Agonists and Antagonists
Chapter 8.	Anticholinesterase Agents
Chapter 9.	Agents Acting at the Neuromuscular Junction and Autonomic Ganglia
Chapter 10.	Adrenergic Agonists and Antagonists
Chapter 11.	5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists
III. Drugs Acting on the Central Nervous System
Chapter 12.	Neurotransmission and the Central Nervous System
Chapter 13.	General Anesthetics
Chapter 14.	Local Anesthetics
Chapter 15.	Therapeutic Gases: Oxygen, Carbon Dioxide, Nitric Oxide, and Helium
Chapter 16.	Hypnotics and Sedatives
Chapter 17.	Drug Therapy of Depression and Anxiety Disorders Latest Update: 08/28/09: Clinical Pharmacist's Corner: Fibromyalgia: Still a Rebel Disease without Definitive Treatment
Chapter 18.	Pharmacotherapy of Psychosis and Mania
Chapter 19.	Pharmacotherapy of the Epilepsies Multimedia: GABAergic Synaptic Transmission: This animation illustrates the workings of a GABAergic synapse, including the actions of gamma-amino butyric acid (GABA) and drugs that affect GABAergic neurotransmission.
Chapter 20.	Treatment of Central Nervous System Degenerative Disorders Multimedia: Dopaminergic Neuroeffector Junction: The key features of a typical dopaminergic neuroeffector junction, including the synthesis, storage, and release of dopamine.
Chapter 21.	Opioid Analgesics
Chapter 22.	Ethanol
Chapter 23.	Drug Addiction and Drug Abuse
IV. Autacoids: Drug Therapy of Inflammation
Chapter 24.	Histamine, Bradykinin, and Their Antagonists
Chapter 25.	Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor
Chapter 26.	Analgesic-Antipyretic and Antiinflammatory Agents; Pharmacotherapy of Gout
Chapter 27.	Pharmacotherapy of Asthma
V. Drugs Affecting Renal and Cardiovascular Function
Chapter 28.	Diuretics
Chapter 29.	Vasopressin and Other Agents Affecting the Renal Conservation of Water
Chapter 30.	Renin and Angiotensin Latest Update: 03/28/08: Clinical Pharmacist's Corner: Aliskiren Hemifumarate (TEKTURNA) First Renin Inhibitor To Be Marketed
Chapter 31.	Treatment of Myocardial Ischemia
Chapter 32.	Therapy of Hypertension Latest Update: 01/29/08: Ambrisentan: A New Drug for Pulmonary Arterial Hypertension
Chapter 33.	Pharmacotherapy of Congestive Heart Failure Latest Update: 07/20/07: Clinical Pharmacist's Corner: Incremental Steps Toward Discerning a Rational Niche for the Combination of Isosorbide Dinitrite and Hydralazine In Chronic Heart Failure Multimedia: Ventricular Myocyte Electrophysiology: This animation will review the electrophysiology of ventricular myocytes, and the pharmacological effects of drugs used to treat ventricular arrhythmias and heart failure.
Chapter 34.	Antiarrhythmic Drugs Latest Update: 08/28/07: Mutation-Specific Pharmacology and Therapeutic Strategies: Lessons from the Congenital Long QT Syndrome Multimedia: Sinus Node Electrophysiology: This animation focuses on the ion channels and transporters that are the primary targets of neurotransmitters of the autonomic nervous system that affect heart rate and drugs used to treat arrhythmias. Multimedia: Atrial Myocyte Electrophysiology: This animation focuses on ion channels and transporters that affect atrial myocyte depolarization, as well as drugs used to treat arrhythmias involving the atria. Multimedia: AV Node Electrophysiology: This animation focuses on the ion channels in the AV node that are the primary targets of neurotransmitters of the autonomic nervous system, and drugs used to treat arrhythmias involving the AV node. Multimedia: Effects of Antiarrhythmic Drugs on the Electrocardiogram: This animation illustrates the effects of various classes of antiarrhythmic drugs on the different regions of the heart and how this results in changes in the electrocardiogram.
Chapter 35.	Drug Therapy for Hypercholesterolemia and Dyslipidemia
VI. Drugs Affecting Gastrointestinal Function
Chapter 36.	Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease
Chapter 37.	Treatment of Disorders of Bowel Motility and Water Flux; Antiemetics; Agents Used in Biliary and Pancreatic Disease
Chapter 38.	Pharmacotherapy of Inflammatory Bowel Disease Latest Update: 05/29/08: Pharmacogenetics of Thiopurines
VII. Chemotherapy of Parasitic Infections
Chapter 39.	Chemotherapy of Protozoal Infections: Malaria Latest Update: 03/12/07: Clinical Pharmacist’s Corner: Update on the Status of Quinine for the Treatment of Nocturnal Leg Cramps
Chapter 40.	Chemotherapy of Protozoal Infections: Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, Leishmaniasis, and Other Protozoal Infections
Chapter 41.	Chemotherapy of Helminth Infections
VIII. Chemotherapy of Microbial Diseases
Chapter 42.	General Principles of Antimicrobial Therapy
Chapter 43.	Sulfonamides, Trimethoprim–Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections
Chapter 44.	Penicillins, Cephalosporins, and Other -Lactam Antibiotics
Chapter 45.	Aminoglycosides
Chapter 46.	Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents Latest Update: 12/01/06: The new and continuing epidemics of drug-resistant Staphylococcus aureus: Daptomycin as a case study in antibiotic development
Chapter 47.	*Chemotherapy of Tuberculosis, Mycobacterium avium* Complex Disease, and Leprosy** Latest Update: 12/01/08: New Advances in the Chemotherapy of Tuberculosis—Part 3 of 3: New Mechanisms Associated with Resistance to Antituberculosis Drugs
Chapter 48.	Antimicrobial Agents: Antifungal Agents
Chapter 49.	Antiviral Agents (Nonretroviral)
Chapter 50.	Antiretroviral Agents and Treatment of HIV Infection Latest Update: 07/28/08: Clinical Pharmacist's Corner: Raltegravir—First Integrase Strand-Transfer Inhibitor
IX. Chemotherapy of Neoplastic Diseases
Chapter 51.	Antineoplastic Agents Latest Update: 06/13/08: Chlorotoxin (TM-601): A Cl^– Channel Blocker Used To Treat Malignant Glioma
X. Drugs Used for Immunomodulation
Chapter 52.	Immunosuppressants, Tolerogens, and Immunostimulants Latest Update: 02/28/08: New Vaccines
XI. Drugs Acting on the Blood and the Blood-Forming Organs
Chapter 53.	Hematopoietic Agents: Growth Factors, Minerals, and Vitamins Latest Update: 08/28/08: Performance-Enhancing Drugs Used by Elite Athletes
Chapter 54.	Blood Coagulation and Anticoagulant, Thrombolytic, and Antiplatelet Drugs Latest Update: 09/29/09: Warfarin Pharmacogenetics Multimedia: Antiplatelet Drugs: This animation illustrates the various mechanisms by which antiplatelet drugs act to prevent normal and pathological thromboses. Multimedia: Parenteral Anticoagulants: This animation reviews the process of coagulation and illustrates the mechanism of action of parenteral anticoagulant drugs. Multimedia: Fibrinolytic Drugs: This animation will review the process of normal fibrinolysis and illustrate the mechanism of drugs that are used to remove pathological fibrin clots. Multimedia: Oral Anticoagulants: This animation will review the synthesis of vitamin K-dependent coagulation factors and illustrate how warfarin acts to inhibit the final step in the synthesis of these clotting factors.
XII. Hormones and Hormone Antagonists
Chapter 55.	Pituitary Hormones and Their Hypothalamic Releasing Hormones
Chapter 56.	Thyroid and Antithyroid Drugs
Chapter 57.	Estrogens and Progestins
Chapter 58.	Androgens
Chapter 59.	Adrenocorticotropic Hormone; Adrenocortical Steroids and Their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones
Chapter 60.	Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas
Chapter 61.	Agents Affecting Mineral Ion Homeostasis and Bone Turnover
XIII. Dermatology
Chapter 62.	Dermatological Pharmacology
XIV. Ophthalmology
Chapter 63.	Ocular Pharmacology
XV. Toxicology
Chapter 64.	Principles of Toxicology and Treatment of Poisoning
Chapter 65.	Heavy Metals and Heavy-Metal Antagonists
Appendices
Appendix I.	Principles of Prescription Order Writing and Patient Compliance
Appendix II.	Design and Optimization of Dosage Regimens: Pharmacokinetic Data

Goodman & Gilman's
Online Features

Grand Rounds View all

Pharmacology of Herbal Remedies and the Placebo Effect
by Arthur P. Grollman, MD

Updates

12/3/2009: St. John’s Wort: A Mini-Review of its Pharmacokinetics and Anti-Depressant Effects Halushka, Perry

9/29/2009: Warfarin Pharmacogenetics Ghimire, Laxmi; Stein, C.

8/28/2009: Clinical Pharmacist's Corner: Fibromyalgia: Still a Rebel Disease without Definitive Treatment Murri, Nelda

View All Updates

Editorial Policy for Updates

The Editors of Goodman & Gilman's welcome your suggestions and submissions for inclusion of updates. If you are a pharmacologist, pharmacist, physician, or medical scientist and you would like the opportunity to contribute an update, please send an email to Editor-in-Chief Laurence Brunton at gg_updates@mhedu.com.

Animations

Flash Player 8 or higher required (Get Flash)

Hemostasis: Antiplatelet, Anticoagulant, and Thrombolytic Drugs:

View all 4 multimedia >

		Oral Anticoagulants

Hide All >

		Antiplatelet Drugs
		Fibrinolytic Drugs
		Oral Anticoagulants
		Parenteral Anticoagulants

Cardiac Electrophysiology and Pharmacology:

View all 5 multimedia >

		Effects of Antiarrhythmic Drugs on the Electrocardiogram

Hide All >

		Atrial Myocyte Electrophysiology
		AV Node Electrophysiology
		Effects of Antiarrhythmic Drugs on the Electrocardiogram
		Sinus Node Electrophysiology
		Ventricular Myocyte Electrophysiology

Neuropharmacology:

View all 4 multimedia >

		GABAergic Synaptic Transmission

Hide All >

		Adrenergic Neuroeffector Junction
		Cholinergic Neuroeffector Junction
		Dopaminergic Neuroeffector Junction
		GABAergic Synaptic Transmission